NCT04653831View on ClinicalTrials.gov

Treatment With Pirfenidone for COVID-19 Related Severe ARDS

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 8, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Covid19ARDS
Interventions
DRUG

Pirfenidone

Treatment with Pirfenidone as mentioned in the experimental arm description.

OTHER

Standard of care

Treatment with SoC as mentioned in the control arm description.

Trial Locations (1)

Unknown

Soroka Medical Center, Beersheba

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Soroka University Medical Center

OTHER

NCT04653831 - Treatment With Pirfenidone for COVID-19 Related Severe ARDS | Biotech Hunter | Biotech Hunter